Davies M, Mawer E B, Krawitt E L
Gut. 1980 Apr;21(4):287-92. doi: 10.1136/gut.21.4.287.
The absorption of simultaneously administered equimolar doses of 14C vitamin D3 and 3H 25 hydroxyvitamin D3 (25-OH-D3) has been studied in controls and patients with a variety of gastrointestinal disorders. As assessed from peak radioactivity in the serum and from faecal excretion of radioactivity, malabsorption of both vitamin D3 and 25-OH-D3 occurred in patients with steatorrhoea. Malabsorption of vitamin D3 was greater than 25-OH-D3. The magnitude of malabsorption of these compounds was related to the severity of the steatorrhoea but was moderate enough to suggest that replacement therapy in patients with intestinal malabsorption should be accomplished with relatively small doses of vitamin D. The more potent vitamin D metabolites are probably unnecessary in this situation.
在对照组以及患有各种胃肠道疾病的患者中，对同时给予等摩尔剂量的14C维生素D3和3H 25-羟基维生素D3（25-OH-D3）的吸收情况进行了研究。从血清中的放射性峰值以及粪便中的放射性排泄物评估，脂肪泻患者中维生素D3和25-OH-D3均出现吸收不良。维生素D3的吸收不良比25-OH-D3更严重。这些化合物吸收不良的程度与脂肪泻的严重程度相关，但程度适中，表明肠道吸收不良患者的替代治疗应以相对小剂量的维生素D来完成。在这种情况下，可能不需要更强效的维生素D代谢产物。
